Objectives: Understanding changing resistance patterns is important in determining appropriate antibiotic treatments. This meta-analysis systematically evaluated resistance of Streptococcus pneumoniae and Streptococcus pyogenes to macrolide antibiotics among patients with community-acquired respiratory tract infections.
Introduction
Macrolide antibiotics are commonly used to treat respiratory tract infections. Three of the most widely used agents in this class are azithromycin (Pfizer), clarithromycin (Abbott) and erythromycin (generic). However, as with other antibiotics, there is increasing global concern regarding the progressive development of bacterial resistance to these agents. The rate of macrolide resistance in Streptococcus pneumoniae has been reported to range from 4 to 70% in worldwide surveillance studies. 1 As discussed by Doern, 2 the most important factor in the development of antimicrobial resistance in S. pneumoniae and other bacteria is the selective pressure applied from the inappropriate and widespread overuse of antibiotics.
A growing recognition of the multifaceted problem of antimicrobial resistance led to the formation of the Federal Interagency Task Antimicrobial Resistance, provides the USA with a comprehensive approach to combat antimicrobial resistance. 3 This report addressed four main areas: surveillance, prevention and control, research, and product development. Readily available public access to reliable drug susceptibility and resistance data is essential for monitoring antimicrobial patterns as they evolve and change over time. Similarly, the World Health Organization launched a campaign in late 2001 known as the Global Strategy for Containment of Antimicrobial Resistance to address the concern that, while national efforts are important, international travel and trade necessitates a global approach to resistance surveillance.
Many studies on macrolide resistance have been conducted. However, the small sample sizes result in limited power to detect statistically significant differences. Meta-analysis is an analytic technique for systematically combining outcomes across multiple studies. This technique allows a more robust determination of outcome values and has increased power to detect statistical significance. The objective of this study was to quantify the extent of macrolide resistance in S. pneumoniae.
Methods
There were four components to this meta-analysis: literature search, development of inclusion criteria, article review and data abstraction, and analysis.
Literature search
Literature searches were performed to identify articles eligible for review. Searches were conducted in MEDLINE and EMBASE. All searches included the terms: (azithromycin OR zithromax OR clarithromycin OR biaxin OR erythromycin) AND ('drug resistance, bacterial' OR 'drug resistance, multiple' OR 'clinical trial [publication type]'). Searches were not limited by age group, i.e. paediatric or adult, or by condition. Literature searches for information on resistance to other macrolides were conducted and no published information was identified. Table 1 presents the inclusion criteria used to identify eligible articles. Use of data only from studies presenting resistance results for each macrolide individually rather than results for all macrolides combined allowed us to also assess medication-specific outcomes. This also resulted in exclusion of a number of broad surveillance studies that reported resistance only for all macrolides combined or did not report resistance associated with specific disease conditions. When data in an abstract or article were unclear, attempts were made to contact the authors for additional information (e.g. dates of data collection, MICs).
Inclusion criteria

Article review and data abstraction
The article review process required the completion of an eligibility check for each article. Each article was reviewed by two independent reviewers. Any differences for inclusion/exclusion or in data abstraction were discussed with the study director (M.T.H.) to reach consensus. Articles meeting the eligibility criteria were abstracted into data tables. All articles that were evaluated for inclusion were also subject to a review of references. In this manner, all publications and reports that were referenced in the retrieved articles were also appraised for potential inclusion in the meta-analysis. In addition, attempts were made to contact authors of included publications to determine whether they had participated in any more recent studies that they could share (i.e. papers in progress or in press). Data abstracted from each article included the study population characteristics, the sample size for each treatment group, and the percent resistant for the overall population and key subgroups. Outcomes from subgroups were also collected during the data abstraction process.
Analysis
Meta-analyses were performed using the random-effects model. 4 This approach was used to assess the extent of bacterial resistance to macrolides of the entire relevant patient population, not only of patients participating in the included studies. Analyses were conducted on endpoints presented in four or more studies. Subgroup analyses were also performed if data were available from four or more studies. Heterogeneity of studies included in meta-analyses was assessed using the Q-statistic. 4 Statistical equivalence between meta-analysis results was assessed using the method of Farrington and Manning, 5 modified for the meta-analysis by using the average number of subjects per study as the n for each group.
Results
Studies and endpoints
We reviewed 3849 publications from MEDLINE and EMBASE published from 1998 to 2003 (see Figure 1) . Candidate articles underwent a three-stage review; first, titles were reviewed in order to determine which abstracts to review; secondly, 1277 abstracts were reviewed to determine which full articles to review; and finally, 407 articles were reviewed for inclusion. with the following infectious disease conditions: tonsillitis, pharyngitis, acute sinusitis, otitis media, community-acquired pneumonia or acute exacerbations of chronic bronchitis Defined inclusion and exclusion criteria for study participants Specification of the criteria for defining resistance (i.e. MIC defined as resistant) Presentation of resistance results by bacterial species, if more than one species was included Presentation of resistance results by patient condition (infectious disease), if more than one condition was included Specification of the number of isolates of each bacterial species for which resistance was determined Evaluation of resistance among bacteria identical to in vivo isolates (i.e. not studies evaluating resistance among bacteria subjected to in vitro modifications) Presentation of separate resistance values for each country or each region
Reasons for exclusion are listed in Table 2 . Reports from a number of broad surveillance studies (e.g. PROTEKT) were excluded from this meta-analysis as they either did not provide resistance information separately for each macrolide (i.e. they presented pooled results across macrolides) and/or they did not provide resistance information for patients with only the selected disease conditions (e.g. lower respiratory tract infections). A total of 29 reports were included in the meta-analysis ( Table 3) .
As specified a priori in our analysis plan, meta-analyses were performed for outcomes for which there were four or more observations that could be aggregated. Analyses were conducted across treatment for selected primary endpoints, including resistance of S. pneumoniae to azithromycin and erythromycin and resistance of Streptococcus pyogenes to erythromycin (Tables 4-6) .
Not all a priori specified endpoints could be analysed. There were three or fewer studies available to examine resistance of S. pneumoniae to clarithromycin, and of S. pyogenes to azithromycin and clarithromycin.
Subgroup (secondary) analyses for one or more endpoints above were conducted for several condition-, age-, setting-and geographic-defined subgroups. A full listing of subgroup analyses appears in Table 7 .
The meta-analysis of azithromycin resistance among S. pneumoniae isolates indicated significant heterogeneity (P < 0.05). The majority of this heterogeneity (78%) was due to a single study. 6 When this study was removed from the analysis, the remaining four studies did not show significant heterogeneity. Therefore, the azithromycin meta-analysis was conducted with only the four remaining studies. None of the other analyses or subgroup analyses demonstrated significant heterogeneity.
Primary analyses
The primary objective of the analysis was to evaluate the extent of bacterial resistance to specific macrolides. Results of the primary analyses are presented in Table 8 . The mean resistance to azithromycin was 27.2% of S. pneumoniae isolates [95% confidence interval (CI) 24.6 -29.7]; mean resistance to erythromycin (30.4%) was similar and not statistically different (95% CI 28.1 -32.7). Equivalence testing using the approach of Farrington and Manning 5 demonstrated equivalence in resistance rates between azithromycin and erythromycin based on the difference between the rates being < 10% (P < 0.05). There were insufficient data to perform meta-analysis on S. pneumoniae resistance to clarithromycin. Resistance of S. pyogenes to erythromycin was similar to S. pneumoniae resistance to erythromycin (30.0%; CI 18.6-41.5).
Subgroup analyses
Age. Resistance of S. pneumoniae to erythromycin (17 studies included in the analysis) and S. pyogenes to erythromycin (five studies) was examined in a paediatric population. Of these 17 studies, 13 included only healthy individuals while four were in patients with infectious disease. S. pneumoniae resistance to erythromycin (33.1%; CI 29.6 -36.7) was greater than the resistance calculated for S. pyogenes (30.0%; CI 18.6-41.5). For S. pneumoniae, an additional analysis was conducted for a healthy paediatric population (13 studies). In this group, the resistance of S. pneumoniae to erythromycin was slightly lower than among the entire paediatric population (28.8%; CI 24.9 -32.8).
Geography. Seven studies in the USA examined S. pneumoniae resistance to erythromycin (20.7%; CI 17.0-24.4) presented in 7. Overall, the percentage of erythromycin-resistant S. pneumoniae in the USA was less than that noted in Europe (32.0%; CI 23.8 -40.3; six studies). This difference was not statistically significant. S. pneumoniae in Asia demonstrated significantly higher levels of resistance to erythromycin than that seen in the USA (57.3%; CI 36.6-77.9; four studies). In Europe, S. pyogenes showed greater resistance than did S. pneumoniae to erythromycin (36.8%; CI 22.5-51.2; four studies).
Condition. When all the conditions were combined (acute exacerbation of chronic bronchitis, acute sinusitis, community acquired pneumonia, otitis media, tonsillitis or pharyngitis), S. pneumoniae in patients with any infectious condition were Setting. Subgroup analyses were conducted for isolates taken from outpatient clinics versus community settings. In this context, 'outpatient settings' refer to patients who presented at outpatient health-care facilities (e.g. hospital clinics), while 'community settings' indicates general populations from whom samples were collected in non-health-care locations (i.e. in the community). S. pneumoniae from outpatient settings was more resistant to erythromycin (37.6%; CI 30.6-44.7; nine studies) than S. pneumoniae taken from the community (28.3%; CI 24.4-32.2; 12 studies). We did not identify any studies in which bacteria were isolated from inpatients. S. pyogenes from outpatient settings demonstrated erythromycin resistance similar to S. pneumoniae from outpatients (37.0%; CI 23.6-50.5; four studies).
Discussion
The meta-analysis technique allowed us to pool results of smaller studies to robustly quantify resistance to selected macrolide antibiotics. The results for all conditions of interest and across all regions indicate that the mean resistance to azithromycin was 27.2% of S. pneumoniae isolates (95% CI 24.6 -29.7); mean resistance to erythromycin for S. pneumoniae was statistically equivalent (30.4%; CI 28.1 -32.7) and also similar to erythromycin resistance in S. pyogenes (30.0%; CI 18.6 -41.5). S. pneumoniae resistance to erythromycin varied by region, from 20.7% in the USA to 57.3% in Asia. S. pneumoniae resistance was also higher among individuals with infectious diseases (35.9%) than among healthy controls (26.9%), perhaps reflecting the selective pressure of prior recent antibiotic therapy. Use of data only from studies presenting resistance results for each macrolide individually rather than results for all macrolides combined allowed us to also compare differences between antibiotics.
There are several limitations of this meta-analysis. Of the 407 articles and abstracts fully evaluated for this meta-analysis, only Data on resistance to azithromycin from Sokol 41 were not included in the meta-analysis as these data resulted in statistically significant (P < 0.05) heterogeneity based on the Q-statistic (as discussed in Methods). AZM, azithromycin; CLR, clarithromycin; ERY, erythromycin.
29 published reports met our strict inclusion criteria. Several studies that we reviewed were not included because either they did not report on the outcomes of interest or did not meet other a priori inclusion criteria. In addition, it is possible that there is a publication bias where studies reporting low levels of resistance would be less likely to be published. However, given the nature of this topic, it is likely that there would be equal interest in reports of low or high levels of resistance. It is therefore unlikely that any significant publication bias has affected our analysis.
Another limitation of any meta-analysis is in the combination of data from diverse sources, study populations and treatment protocols. While the inclusion criteria used for this study help to reduce heterogeneity, we cannot be certain that these studies are fully comparable. However, use of a statistical tool to assess potential heterogeneity among included studies (the Q-statistic) gives us further confidence in the meta-analysis results.
A greater proportion of articles included in the meta-analysis were from paediatric than from adult studies. This is not a surprising finding and may relate to the greater prevalence and frequency of medical visits by the paediatric population. Furthermore, these were the articles that met the a priori inclusion criteria, and thus represent an unbiased sample within these criteria.
Ideally, in addition to quantifying bacterial resistance, this analysis would also have explored the link between resistance and patient outcomes. However, a majority of the studies included in the meta-analysis did not provide information on patient outcomes. Thus, we were unable to evaluate this important link. Future studies of antibiotic resistance in community settings should include data on patient outcomes whenever possible to permit further exploration of the impact of resistance on outcome.
Finally, a number of large surveillance studies that are often used to discuss resistance did not meet our inclusion criteria. For example, several studies were excluded because they did not provide results separately by type of infectious disease (e.g. Farrell et al. 7 and Felmingham et al.
8
). However, results from these surveillance studies provided similar results to those of the current meta-analysis. For example, Felmingham et al. 8 reported that overall resistance of S. pneumoniae to erythromycin from the PROTEKT study was 31.1% (similar to our value of 30.4%, presented in Table 8 ). Resistance to azithromycin from this study was also 31.1%, similar to the meta-analysis value of 27.2%. Geographic variation in resistance rates also showed a similar pattern to the meta-analysis, although rates from PROTEKT tended to be higher. Thus, information on resistance collected in broad surveillance studies corroborates the results found in the meta-analysis.
Breakpoints used for determining bacterial resistance are also a crucial component in combining multiple studies of resistance. By limiting the studies by years of publication, we anticipated that breakpoints would be less likely to differ among the included studies. This was not entirely the case, as the most frequently cited breakpoints, those of the NCCLS, did vary from the 1993 to 2002 versions. However, the actual breakpoints used were very similar across the included studies and did not differ systematically (i.e. by region, country or date of publication). Despite these limitations, this meta-analysis provides an important synthesis of the reported macrolide resistance rates for S. pneumoniae and S. pyogenes. Based on these results, macrolide resistance is consistently present in a sizeable proportion of multiple populations. As interest in resistance patterns and rates of common pathogens to antibiotics increases, these results can be used to influence treatment decisions and to formulate consensus recommendations for appropriate treatment paradigms. The meta-analysis technique used here can help to develop appropriate guidelines governing antibiotic use and to monitor drug resistance trends. Generally, rates of resistance in community-based studies are lower than in surveillance studies. For example, as recently presented by Bonvehi et al., 9 documented clarithromycin treatment failure rates were lower than the values that would have been predicted based on resistance rates from surveillance studies. These authors conclude that 'relevant resistance in the community may not be predicted by in vitro surveillance studies.' Nuermberger and Bishai 10 recently indicated similar conclusions in a review of macrolideresistant S. pneumoniae. These authors reported that macrolide concentrations in alveolar epithelial lining fluid are higher than those in plasma, which may account for lower rates of macrolide treatment failure than predicted by in vitro resistance data. They further state that additional clinical data from large-scale observational studies will be needed to evaluate the link between in vitro macrolide resistance and treatment failure. Thus, analyses of community-based experiences can provide an important contribution to the understanding of real-world resistance issues from the perspective of day-to-day medical practice.
Rising rates of antibiotic resistance have a major impact on the ability of physicians to treat common infections. Patients may face more severe infections with increased duration as resistance increases; they may also experience heightened toxicity associated with the use of stronger antibiotics. Clinicians may eventually encounter infections caused by highly resistant pathogens for which no effective antibiotics are available. Preventative strategies coupled with the development of new generations of medications are necessary to ensure the continued availability of appropriate antibiotic therapy. In addition, antibiotic resistance undoubtedly has economic impacts, but these costs have not been well delineated. 11 Economic studies of bacterial resistance have in general focused on inpatient facilities and Gram-positive infections. While these studies have reported substantial increases in length of stay and costs, 12 -14 more work is need to evaluate the impact of resistance in outpatient and community settings.
In 2003, experts in a wide range of therapeutic specialties convened the Start Treatment with Appropriate Antibiotic Therapy (STAART) working group to discuss important issues surrounding the treatment of patients with community-acquired respiratory tract infections. The panel evaluated the hypothesis that the initial use of a tailored antimicrobial (i.e. with specific bactericidal activity and related characteristics) in relevant patients may be associated with improved clinical and microbiological outcomes and a decreased risk of resistance. This group defined the appropriate antimicrobial agent as one that has a focused spectrum of activity against common respiratory pathogens, resistant pathogens and atypical pathogens while having little activity on other endogenous microbial flora.
This meta-analysis demonstrates that resistance to macrolides is a significant issue in the USA as well as in Europe and Asia. Reported macrolide resistance in S. pneumoniae varies greatly from country to country and is likely to be an important problem in certain regions. Further work needs to be done in Australia, Canada, South America and Africa; an insufficient number of studies prevented these areas from being included in the subgroup meta-analyses. Given the range of modern travel and easy carriage of resistant organisms, further antibiotic resistance surveillance studies in these regions are important.
In summary, this meta-analysis has provided important information on resistance by S. pneumoniae and S. pyogenes to macrolide antibiotics. The use of the meta-analysis technique has allowed us to summarize data from individual studies and to determine robust values for both overall resistance and resistance among subgroups. These results will be useful in developing future guidelines and treatment paradigms for S. pneumoniae and S. pyogenes, as well as in helping to direct future research on the impact of bacterial resistance and appropriate antimicrobial use. 
